360
Participants
Start Date
May 31, 2014
Primary Completion Date
May 31, 2015
Study Completion Date
June 30, 2015
Drug: PRC-063
Methylphenidate Hydrochloride Extended-Release Capsules
PRC-063
Methylphenidate Hydrochloride Extended-Release Capsules
Medical Research Network, New York
NeuroScience, Herndon
Wake Research Associates, Raleigh
CNS Healthcare Jacksonville, Jacksonville
Sarkis Clinical Research, Gainesville
Sarkis Clinical Trials, Gainesville
Florida Clinical Research Center, Maitlin
Clinical Neuroscience Solutions, Orlando
Florida Clinical Research Center, Bradenton
Clinical Neuroscience Solutions Inc., Memphis
University of Cincinnati, Cincinnati
IPS Research Company, Oklahoma City
FutureSearch Trials of Dallas, L.P., Dallas
Red Oak Psychiatry Associates, Houston
Houston Clinical Trials, Houston
FutureSearch Clinical Trials, L.P., Austin
Westex Clinical Investigations, Lubbock
Advanced Clinical Research, Boise
Ericksen Research, Clinton
Physiciatric and Behavioral Solutions, Salt Lake City
Center for Psychiatry and Behavioral Medicine Inc., Las Vegas
UCLA, Los Angeles
Synergy Clinical Research, National City
Newport Beach Clinical Research Associates, Inc., Newport Beach
Oregon Center for Clinical Investigation, Portland
Orange County Neuro Phychiatry Research Centre, Orange
Oregon Center for Clinical Investigation, Salem
Northwest Clinical Research Center, Friday Harbor
Eastside Therapeutic Resource, Kirkland
Woodstock Research Center at Neuropsychiatric Associates, Woodstock
Dr. Margaret Weiss, Vancouver
Doctors Jackiewicz Professional Medical Corporation, Niagara Falls
Dr. Judy van Stralen, Ottawa
The Kids Clinic, Whitby
Diex Research Sherbrooke Inc., Sherbrooke
Purdue Pharma LP
INDUSTRY
Rhodes Pharmaceuticals, L.P.
INDUSTRY